Use of Potentially Hepatotoxic Drugs in Liver Cirrhosis Patients: A Review
Article Sidebar
Main Article Content
Page: 766-771
Abstract
Liver cirrhosis is a pathological liver disease characterized by the formation of scar tissue and regenerative nodules in liver cells. This condition leads to changes in the shape and size of the liver, accompanied by increased pressure in the veins and reduced blood flow in the portal vein. Liver cirrhosis is the seventh leading cause of death. Drugs are the main cause of liver damage. More than 900 drugs, toxins and herbs are reported to cause liver damage. The purpose of this review article is to summarize the results of previous studies on the use of hepatotoxic drugs in patients with liver cirrhosis. Data sources for this study were identified through searching Google Scholar, PubMed and Science Direct using the keywords "hepatotoxic drugs" and "liver cirrhosis" in articles published between 2011-2022. Finally, 10 articles were obtained and analyzed. The results of this review article show that liver cirrhosis patients are still often prescribed potentially hepatotoxic drugs. Some commonly prescribed drugs include paracetamol, omeprazol, ranitidine, ceftriaxon, ciprofloxacin, atorvasatin, metformin, and amiodarone.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Amarapurkar, D.N. (2011). Prescribing Medications in Patients with Decompensated Liver Cirrhosis. Internasional Journal of Hepatology, vol 2011:519526.
Anindyaguna, A., Mustofa, S., Anggraini,D.I., Oktarlina, R.Z. (2022). Drug-Induced Liver Injury Akibat Penyalahgunaan Parasetamol. Medula vol. 12:3.
Cheney, C.P., Goldber, E.M., Chopra, S. (2012). Cirrhosis and Portal Hypertension: an overview. In: Friedman, L.S, Kheffe, E.B. Handbook of Liver Disease. Philadelphia: Elsevier Inc. Pp. 136-148.
Dewi, T., Masruhim, M.A., Sulistiarini, M. (2016). Identifikasi Obat Penginduksi Kerusakan Hati Pada Pasien Hepatitis Di Rumah Sakit Abdul Wahab Sjahranie. Dalam Seminar Nasional Kefarmasian Ke-III. Samarinda, 20-21 April 2016. Samarinda. Fakultas Farmasi Universitas Mulawarman.hal 151-157.
Dipiro, J.T., Dipiro, C.V., Wells, B.G., & Scwinghammer, T.L. (2017). Pharmacoteraphy Handbook Tenth Edition. USA : McGraw-Hill Company.
Fukui, H., Kawaratani, H., Kaji, K., Takaya, H., Yoshiji, H. (2018). Management of Refractory Cirrhotic Ascites: Challenges and Solutions. Hepat Med. 10:55-71.
Khalili, M., & Burman, B. (2014). Liver Disease Pathophysiology of Disease: An Introduction To Clinical Medicine, Ed. 7th. USA: The McGraw-Hill Companies.
Katarey., Dev, V., Sumita. (2016). Drug-induced Liver Injury. Clinical Medicine s104–s109.
LiverTox. (2018). Ranitidine. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
LiverTox. (2018). Insulin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
LiverTox. (2019). Omeprazole. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
LiverTox. (2020). Metformin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
Nurdjanah, S. (2014). Sirosis Hati. Dalam Buku Ajar Ilmu Penyakit Dalam, edisi 6, jilid 2, hal 1978-1983. Jakarta: Internal publishing.
Pandit, A., Sachdeva, T., Bafna, P. (2012). Drug-Induced Hepatotoxicity: A Review. Journal of Applied Pharmaceutical Science 02 (05): 233-243.
Parsian, H., Nouri, M., Rahimipour, A., Hossein, M., & Qujeq, D. (2011). Comparison of Five Liver Fibrosis Indexes with Serum Levels of Laminin and N Terminal Peptide of Procollagen Type III in Chronic Hepatitis Patients. Liver Biopsy.
Robiyanto, R., Liana, J., Purwanti, N.U. (2019). Kejadian Obat-obatan Penginduksi Kerusakan Liver pada Pasien Sirosis Rawat Inap di RSUD Dokter Soedarso Kalimantan Barat. Jurnal Sains Farmasi & Klinis 6(3):274-285.
Sharma, B., & John, S. (2022). Hepatic Cirrhosis. StatPearls Publishing.
Sibuea, C.V., Hutabarat, E.S.K., & Simangunsong, D.M. (2022). Viabilitas Hepatosit pada Monokultur 3D Metode Hanging Drop dan Monokultur 2D. Nommensen Journal of Medicine 7(2):36-38.
Teschke, R., Danan, G. (2017). Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?. Expert Opin Drug Metab Toxicol 13(4):425–438.
Walter dan Brian. (2020). Episode 148 Liver Emergencies Part 1: Acute Liver Failure, Hepatic Encephalopathy, Hepatorenal Syndrome, Liver Test Interpretation & Drugs to Avoid. EM Cases Summary.
Zhou, W.C., Zhang, Q.B., Qiao, L. (2014). Pathogenesis of Liver Cirrhosis. World Journal of Gastrology 20(23):7312-7324.